SMC approves three new medicines for NHS Scotland

SMC approves three new medicines for NHS Scotland PharmacoEconomics & Outcomes News 784, p36 - 12 Aug 2017 SMC approves three new medicines for NHS Scotland The Scottish Medicines Consortium (SMC) has approved three new medicines for routine use by NHS Scotland. Firstly, carfilzomib (Kyprolis) was accepted for use in combination with dexamethasone for the treatment of patients with multiple myeloma. Compared with other current treatments, carfilzomib has a more favourable adverse events profile and has been associated with increased overall and progression-free survival. Secondly, venetoclax (Venclyxto) was accepted by the SMC for the treatment of chronic lymphocytic leukaemia. Venetoclax can potentially improve quality of life and significantly reduce symptoms in this patient group, with participants in the consideration process emphasising that they have limited options when initial treatments fail or are unsuitable. Both carfilzomib and venetoclax were considered via SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines for very rare conditions. Lastly, the SMC accepted desmopressin for the treatment of idiopathic nocturnal polyuria. However, a lack of comparable cost effectiveness meant that 5-aminolaevulinic acid hydrochloride gel (Ameluz) was not approved for routine use by NHS Scotland for basal cell carcinomas that are unsuitable for surgical removal. "The company’s evidence on the economic benefits of the medicine compared to other similar treatments was not sufficient for us to accept it for routine use", commented Chairman of the SMC, Dr Alan MacDonald. Scottish Medicines Consortium. August 2017 decisions news release. Internet Document : 7 Aug 2017. Available from: URL: http:// August_2017_decisions_news_release 803263882 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 PharmacoEconomics & Outcomes News Springer Journals

SMC approves three new medicines for NHS Scotland

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial